Weight Loss Drugs - MarketMinute

Weight Loss Drugs

The $49 Disruptor: Hims & Hers Ignites a Brutal Price War in the Weight-Loss Drug Market

The long-standing duopoly of the weight-loss drug market faced its most significant challenge yet this week as Hims & Hers Health, Inc. (NYSE: HIMS) announced a breakthrough $49 compounded oral semaglutide pill. The move, aimed directly at the market share of pharmaceutical titans Eli Lilly and Company (NYSE: LLY) and

Novo Nordisk

The Great Pricing Pivot: Novo Nordisk Launches Wegovy Pill in Bid to Reclaim US Market Dominance

As the first full week of 2026 unfolds, the pharmaceutical landscape is witnessing a seismic shift led by the Danish healthcare giant Novo Nordisk (NYSE: NVO). On January 5, 2026, the company officially launched the oral version of its blockbuster weight-loss drug, Wegovy, in the United States. This move marks

Palantir

Under Pressure: Palantir and Viking Therapeutics Face Investor Scrutiny

The financial markets are a dynamic arena where fortunes can shift rapidly, and the past week has seen two prominent companies, Palantir Technologies Inc. (NYSE: PLTR) and Viking Therapeutics (NASDAQ: VKTX), come under intense investor scrutiny. Despite a year of impressive gains for Palantir, concerns over its valuation have led